Timing and predictors of death during treatment in patients with multidrug/rifampin-resistant tuberculosis in South Korea
- Author:
Eunjeong SON
1
;
Hongjo CHOI
;
Jeongha MOK
;
Young Ae KANG
;
Dawoon JEONG
;
Doosoo JEON
Author Information
- Publication Type:2
- From:The Korean Journal of Internal Medicine 2024;39(4):640-649
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Background/Aims:This study aimed to investigate the timing and predictors of death during treatment among patients with multidrug/rifampin-resistant tuberculosis (MDR/RR-TB) in South Korea.
Methods:This was a retrospective cohort study that included MDR/RR-TB cases notified between 2011 and 2017 in South Korea.
Results:Among 7,226 MDR/RR-TB cases, 699 (9.7%) died at a median of 167 days (IQR 51–358 d) from the initiation of MDR-TB treatment. The cumulative proportion of all-cause death was 35.5% at 90 days and 52.8% at 180 days from treatment initiation. TB-related deaths occurred at a median of 133 days (IQR 32–366 d), which was significantly earlier than the median of 184 days (IQR 68–356 d) for non-TB-related deaths (p = 0.002). In a multivariate analysis, older age was the factor most strongly associated with death, with those aged ≥ 75 years being 68 times more likely to die (aHR 68.11, 95% CI 21.75–213.26), compared those aged ≤ 24 years. In addition, male sex, comorbidities (cancer, human immunodeficiency virus, and end stage renal disease), the lowest household income class, and TB-specific factors (previous history of TB treatment, smear positivity, and fluoroquinolone resistance) were identified as independent predictors of all-cause death.
Conclusions:This nationwide study highlights increased deaths during the intensive phase and identifies high-risk groups including older people and those with comorbidities or socioeconomic vulnerabilities. An integrated and comprehensive strategy is required to reduce mortality in patients with MDR/RR-TB, particularly focusing on the early stages of treatment and target populations.
